United States - English - NLM (National Library of Medicine)

a-s medication solutions - liraglutide (unii: 839i73s42a) (liraglutide - unii:839i73s42a) - victoza is indicated: infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies ( 14.3 )] . limitations of use : victoza should not be used in patients with type 1 diabetes mellitus. victoza contains liraglutide and should not be coadministered with other liraglutide-containing products. victoza is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (mtc) or in patients with multiple endocrine neoplasia syndrome type 2 (men 2). victoza is contraindicated in patients with a serious hypersensitivity reaction to liraglutide or to any of the excipients in victoza. serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with victoza [see warnings and precautions (5.6)]. risk summary based on animal reproduction studies, there may be risks to the fetus from exposure to victoza during pregnancy. victoza should be used during pregnancy only if the potentia

United States - English - NLM (National Library of Medicine)

a-s medication solutions - liraglutide (unii: 839i73s42a) (liraglutide - unii:839i73s42a) - victoza is indicated: infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies ( 14.3 )] . limitations of use : victoza should not be used in patients with type 1 diabetes mellitus. victoza contains liraglutide and should not be coadministered with other liraglutide-containing products. victoza is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (mtc) or in patients with multiple endocrine neoplasia syndrome type 2 (men 2). victoza is contraindicated in patients with a serious hypersensitivity reaction to liraglutide or to any of the excipients in victoza. serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with victoza [see warnings and precautions (5.6)]. risk summary based on animal reproduction studies, there may be risks to the fetus from exposure to victoza during pregnancy. victoza should be used during pregnancy only if the potentia

Israel - English - Ministry of Health

novo nordisk ltd., israel - liraglutide - solution for injection - liraglutide 6 mg / 1 ml - liraglutide - adultssaxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of •≥30 kg/m² (obesity), or •≥27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension or dyslipidaemia, and who have failed a previous weight management intervention. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.adolescents (≥12 years)saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with:• obesity (bmi corresponding to ≥30 kg/m2 for adults by international cut-off points)* and• body weight above 60 kg. treatment with saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their bmi or bmi z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. re-evaluation should be performed periodically

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - albiglutide - diabetes mellitus, type 2 - drugs used in diabetes - eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:monotherapywhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.add-on combination therapyin combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - semaglutide -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - semaglutide -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - semaglutide -

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - diabetes mellitus, type 2 - drugs used in diabetes - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - antiobesity preparations, excl. diet products - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.